WIP1 Antibody

What is WIP1 and what are its primary functions in cellular pathways?

WIP1, also known as PPM1D (protein phosphatase, Mg²⁺/Mn²⁺ dependent 1D), is a p53-inducible serine/threonine phosphatase that plays crucial roles in switching off DNA damage checkpoint responses. The human WIP1 protein has a canonical amino acid length of 605 residues and a molecular mass of 66.7 kilodaltons, although two isoforms have been identified .

WIP1's primary functions include:

• Dephosphorylation of key proteins in DNA damage response (DDR) pathways including p53, ATM/ATR, and checkpoint kinases

• Modulation of cell cycle progression through p53 pathway regulation

• Participation in homologous recombination (HR) DNA repair mechanisms

• Regulation of B-cell development through p53-dependent pathways

• Suppression of apoptotic signaling through direct dephosphorylation of BAX

WIP1 is localized primarily in the nucleus and cytoplasm, with notable expression in tissues such as the caudate, tonsil, and adrenal gland . The murine and human WIP1 protein sequences share approximately 83% identity and 86% similarity .

What applications are WIP1 antibodies most commonly used for in research?

WIP1 antibodies are versatile research tools employed across multiple immunological techniques:

When selecting WIP1 antibodies, researchers should consider their experimental goals. For instance, the mouse monoclonal F-10 antibody (sc-376257) reacts with WIP1 protein from mouse, rat, and human origins, making it suitable for cross-species experiments . Other antibodies like OTI3E1 (ab236515) specifically target human samples .

What are the challenges in detecting specific WIP1 isoforms?

Detecting specific WIP1 isoforms presents several methodological challenges:

• Multiple bands observed in Western blots: Research indicates that WIP1 antibodies (particularly the F-10 clone) can detect multiple bands, including the full-length WIP1 (≈66-67 kDa) and shorter isoforms such as S*-WIP1 (≈55 kDa) .

• Validating specificity: Validation using siRNA knockdown is crucial. Studies have shown that PPM1D siRNA constructs reduce the intensity of multiple bands detected by WIP1 antibodies, suggesting all detected bands correspond to WIP1 isoforms .

• Cell-line dependent expression patterns: Different cell lines express varying levels of WIP1 isoforms. For example, PPM1D-amplified MCF-7 cells show high basal expression of WIP1 and its isoforms .

• Detecting truncated forms: Some cell lines express truncated and activating WIP1-mutant proteins such as WIP1 L450X and WIP1 R458X, which require specific detection methods .

Methodologically, researchers should include appropriate controls (siRNA knockdown samples), use multiple antibodies targeting different epitopes, and analyze their samples alongside well-characterized cell lines to accurately identify specific isoforms.

How should researchers select appropriate controls for WIP1 antibody experiments?

Effective control selection is critical for WIP1 antibody experiments:

• Positive controls: Cell lines with known WIP1 expression patterns should be used:

  • MCF-7 cells (PPM1D-amplified) show high WIP1 expression

  • NGP cells (with PPM1D copy number gain) display moderate expression

  • SJSA-1 cells (wild-type PPM1D) exhibit lower expression levels

• Negative controls:

  • WIP1 knockout cell lines (U2OS-WIP1-KO or RPE-WIP1-KO) generated via CRISPR/Cas9 technology

  • Cells treated with siRNA targeting PPM1D

• Specificity controls:

  • Complementation experiments using wild-type WIP1 and catalytically inactive D314A mutant to confirm functional effects

  • Paired wild-type and mutant cell lines (e.g., U2OS/U2OS-WIP1-KO) to validate antibody specificity

• Loading controls:

  • For nuclear proteins, TFIIH is recommended as a loading control for Western blotting

These controls help validate antibody specificity and ensure accurate interpretation of experimental results.

How does WIP1 promote homologous recombination, and how can researchers experimentally assess this function?

WIP1 plays a critical role in promoting homologous recombination (HR) DNA repair through multiple mechanisms:

• BRCA1 interaction and dephosphorylation:

  • WIP1 directly interacts with and dephosphorylates BRCA1

  • Loss of WIP1 delays recruitment of BRCA1 to DNA double-strand breaks (DSBs)

  • WIP1 activity is required for correct dynamics of BRCA1 recruitment to chromatin flanking DNA lesions

• 53BP1 regulation:

  • WIP1 dephosphorylates 53BP1 at Threonine 543, which mediates interaction with RIF1

  • This dephosphorylation is critical for 53BP1 repositioning during HR repair

• DNA damage resolution in S/G2 cells:

  • WIP1 knockout or inhibition leads to persistence of 53BP1 foci specifically in S-phase cells after irradiation

  • This persistence indicates unresolved DNA damage in these cells

Experimental assessment methodologies:

Researchers have observed that U2OS-WIP1-KO cells show increased sensitivity to DNA crosslinking agent mitomycin C, consistent with WIP1's role in HR .

What is the relationship between WIP1 and cancer stem cell (CSC) properties, and how can this be experimentally interrogated?

WIP1's role in cancer stem cell (CSC) properties operates primarily through p38 MAPK pathway inhibition:

• Mechanism of action:

  • WIP1 acts as a p38 phosphatase, suppressing p38 MAPK pathway activation

  • Reduced p38 activation leads to increased expression of stemness-related transcription factors in non-small-cell lung cancer (NSCLC) cells

  • Increased WIP1 expression correlates with reduced levels of activated p38 and increased levels of CSC markers in NSCLC tissues

• Experimental evidence:

  • WIP1 inhibitors suppress stemness-related protein expression and CSC properties by reactivating p38 in NSCLC cells both in vitro and in vivo

  • This identifies the WIP1–p38–MK2–HSP27 cascade as a key signaling pathway that promotes CSC properties when altered

Experimental methodologies for investigating WIP1-CSC relationships:

These methods provide comprehensive insights into how WIP1 regulation affects cancer stemness properties through modulation of the p38 MAPK signaling pathway.

What novel assays have been developed for screening WIP1 phosphatase substrates, and what are their applications?

Recent advances have led to the development of specialized assays for identifying and validating WIP1 substrates:

• In vitro assay for testing WIP1 substrates in nuclear extracts:

  • This simple assay allows comparison of WIP1's ability to dephosphorylate various proteins

  • The method aids in identifying physiological substrates of WIP1

  • Using this approach, Deleted in breast cancer gene 1 (DBC1) was identified as a new substrate of WIP1

• Applications of WIP1 substrate screening:

  • Confirmation of known substrates: p53 at S15 was confirmed as a WIP1 substrate using this assay

  • Investigation of p53 acetylation: WIP1 activity was shown to suppress p53-K382 acetylation by inhibiting p53-p300 interaction

  • Exclusion of non-substrates: The assay demonstrated no detectable WIP1 activity toward p38/MK2

• Phosphorylation site mapping:

  • WIP1 dephosphorylates BAX at threonines 172, 174, and 186

  • WIP1 efficiently dephosphorylates 53BP1 at T543 in vitro

  • These findings help elucidate the molecular mechanisms by which WIP1 regulates its targets

• Functional consequence analysis:

  • BAX proteins with mutations at WIP1 target sites fail to translocate efficiently to mitochondria following cellular γ-irradiation

  • This demonstrates how substrate identification can reveal functional consequences of phosphatase activity

These assays provide valuable tools for expanding our understanding of WIP1's substrate repertoire and biological functions.

How does WIP1 inhibition affect sensitivity to PARP inhibitors, and what are the implications for cancer therapy?

WIP1 inhibition significantly increases sensitivity to PARP inhibitors through multiple mechanisms:

• Impairment of homologous recombination (HR):

  • WIP1 deficiency reduces HR efficiency as demonstrated by reporter assays

  • This creates a synthetic lethal interaction with PARP inhibition similar to BRCA1/2 deficiency

• Experimental evidence:

  • U2OS-WIP1-KO cell lines show increased sensitivity to the PARP inhibitor olaparib

  • WIP1 inhibition decreases cell proliferation to a similar extent as WIP1 knockout

  • Complementation with wild-type WIP1, but not catalytically inactive D314A mutant, rescues this sensitivity

  • Decreased cell proliferation after combined treatment with WIP1 inhibitor and olaparib is associated with increased cell death in U2OS cells

  • Similar increases in sensitivity to olaparib and A-966492 (another PARP inhibitor) were observed in MCF7 and RPE cell lines after WIP1 inhibition

• Synergistic effects with other phosphatases:

  • Combined depletion of PP4C and inhibition of WIP1 further increases sensitivity to olaparib

  • This suggests that both phosphatases may target similar substrates involved in HR regulation

• Mechanistic basis:

  • Accumulation of 53BP1 foci in G2 cells after combined treatment with olaparib and WIP1 inhibitor indicates persistent DNA damage

  • This effect is independent of cell cycle checkpoint activation

Clinical implications:

• WIP1 inhibitors could potentially sensitize BRCA1-proficient cancer cells to PARP inhibitors

• This strategy might expand the utility of PARP inhibitors beyond BRCA-mutated cancers

• Monitoring WIP1 expression levels could serve as a biomarker for predicting PARP inhibitor sensitivity

How does WIP1 suppress BAX-mediated apoptosis, and what are the methodological approaches to study this interaction?

WIP1 directly regulates BAX-mediated apoptosis through a novel dephosphorylation mechanism:

• Direct interaction and dephosphorylation:

  • WIP1 physically interacts with BAX protein

  • WIP1 dephosphorylates BAX specifically at threonines 172, 174, and 186

  • This dephosphorylation suppresses BAX-mediated apoptosis in response to γ-irradiation in prostate cancer cells

• Functional consequences:

  • Radiation-resistant LNCaP cells show dramatic increases in WIP1 levels after γ-irradiation

  • These cells display impaired BAX movement to the mitochondria, which is reversed by WIP1 inhibition

  • BAX proteins with mutations at WIP1 target sites fail to translocate efficiently to mitochondria following γ-irradiation

  • Overexpression of WIP1 and BAX, but not phosphatase-dead WIP1, in BAX-deficient cells strongly reduces apoptosis

Methodological approaches to study this interaction:

This research has established BAX dephosphorylation by WIP1 as an important regulator of resistance to anticancer therapy, representing the first report of BAX activity downregulation by a protein phosphatase .

What are the known WIP1 expression patterns in different tissues and developmental stages, and how can researchers accurately quantify WIP1 levels?

WIP1 exhibits distinct expression patterns across tissues and developmental stages:

• Tissue-specific expression:

  • WIP1 is ubiquitously expressed in multiple tissues

  • Particularly high expression is observed in the testis

  • Notable expression in the caudate, tonsil, and adrenal gland

  • Expression levels fluctuate during development

• Cell-type specific patterns:

  • In B-cell development, WIP1 shows increased expression in pro-B and pre-B cells

  • This expression pattern corresponds to WIP1's functional role in early B-cell development in the bone marrow

• Disease-relevant contexts:

  • Increased expression of WIP1 is associated with poor prognosis and lower survival rates in some human cancers

  • WIP1 is amplified or overexpressed in various human tumors

  • PPM1D-amplified cancer cells (e.g., MCF-7) show higher WIP1 expression than non-amplified lines

Methods for accurate WIP1 quantification:

For developmental studies, researchers successfully employed quantitative PCR analysis of purified B-cell subpopulations (pre-pro-B, pro-B, pre-B, immature B, and mature B cells) to establish WIP1's expression pattern during B-cell development .

Human WIP1, mice 5 months old post-experimental vs. wt mice. Compared *p < .001; Figure 1A.

For tissue-specific expression analysis, semi-quantitative Western blotting with proper controls and standardization can provide reliable expression data across different tissues and experimental conditions.

Human studies must include appropriate positive controls (such as MCF-7 cells) and negative controls (WIP1 knockout or knockdown samples) to ensure accurate quantification and interpretation of results.

What are the key methodological considerations when using WIP1 inhibitors in experimental settings?

When utilizing WIP1 inhibitors in research, several critical methodological aspects must be considered:

• Inhibitor selection and specificity:

  • GSK2830371 (commonly referred to as WIP1i) is a widely used specific WIP1 inhibitor

  • Working concentration is typically 0.5 μM unless specified otherwise for particular cell lines or experimental conditions

  • Vehicle controls (DMSO) are essential as WIP1 inhibitors are typically dissolved in DMSO

• Validation of inhibition:

  • Western blotting for phosphorylation of known WIP1 substrates (e.g., p53-S15, 53BP1-T543, KAP1-S824)

  • Functional rescue experiments using WIP1 overexpression to confirm specificity

  • Comparison with genetic knockout models to validate inhibitor effects

• Cell line-specific considerations:

  • Sensitivity to WIP1 inhibition varies across cell lines

  • PPM1D-amplified MCF-7 cells show high sensitivity to GSK2830371 single treatment

  • Cell lines with different p53 status may respond differently (compare effects in paired p53 wild-type and mutant cell lines)

• Combination treatments:

  • When combining with other agents (e.g., PARP inhibitors, radiation):

    • Proper sequence and timing of administration must be established

    • Concentration-effect relationships should be determined for each agent alone and in combination

    • Appropriate controls for each treatment and their combinations are essential

• Readout selection:

  • Cell proliferation assays: Measure decreased cell proliferation after WIP1 inhibition

  • Apoptosis assays: Assess increased cell death after combined treatment with WIP1 inhibitor and other agents

  • DNA damage assays: Monitor persistence of γH2AX or 53BP1 foci to assess DNA repair defects

  • Protein phosphorylation status: Examine target phosphorylation by Western blotting or immunofluorescence